Skip to main content
. 2019 Nov 8;20(22):5579. doi: 10.3390/ijms20225579

Table 2.

Monoclonal antibodies and their tumor-specific antigen used for RIT.

Monoclonal Antibody Targeted Site
Trastuzumab (Herceptin, Roche, Basel, Switzerland) HER2
Bevacizumab (Avastin, Genentech, CA, USA) VEGF-A
Cetuximab (Erbitux, Kenilworth, NJ, USA) EGFR
Rituximab (Rituxan, Genentech, CA, USA) CD20
Tositumomab (Bexxar, Genentech, CA, USA) CD20
Ibritumomab tiuxetan (Zevalin, Biogen Idec, Cambridge, MA, USA) CD20